v3.25.3
Segment Reporting - Summary of Segment Profit or Loss, Including Significant Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]                
Collaboration revenue $ 20,750           $ 50,146  
Research and development expense 67,908     $ 41,705     186,666 $ 117,700
Share-based compensation expense 10,965     8,324     25,756 25,266
Total operating expenses 100,747     59,884     267,509 170,740
Other income (expenses):                
Interest and other income 6,274     5,892     21,088 17,190
Income tax expense             (226)  
Net Loss (74,116) $ (66,122) $ (57,429) (54,404) $ (50,837) $ (49,525) (197,667) (154,766)
Operating Segments                
Segment Reporting Information [Line Items]                
Collaboration revenue 20,750           50,146  
Research and development expense 13,695     11,474     41,790 32,611
Share-based compensation expense 10,965     8,324     25,756 25,266
Other segment expenses 25,086     13,425     64,340 38,992
Total operating expenses 100,747     59,884     267,509 170,740
Other income (expenses):                
Interest and other income 6,274     5,892     21,088 17,190
Interest expense (393)     (412)     (1,166) (1,216)
Income tax expense             (226)  
Net Loss (74,116)     (54,404)     (197,667) (154,766)
Operating Segments | Ziftomenib                
Segment Reporting Information [Line Items]                
Research and development expense 40,320     18,993     107,851 52,335
Operating Segments | Darlifarnib                
Segment Reporting Information [Line Items]                
Research and development expense 8,494     5,178     19,871 13,026
Operating Segments | Tipifarnib                
Segment Reporting Information [Line Items]                
Research and development expense 443     721     2,578 3,560
Operating Segments | Discovery Stage Program                
Segment Reporting Information [Line Items]                
Research and development expense $ 1,744     $ 1,769     $ 5,323 $ 4,950